In 2019, six key tasks of drug administration were launched: improving vaccine supervision, reviewing and approving reform, accelerating the construction of standard system

On January 10-11, the national drug regulatory working conference was held in Beijing The conference, guided by Xi Jinping's socialist ideology with China's characteristics, conscientiously implemented the spirit of the nineteen and third Plenary Session of the nineteen and second Central Committee of the party, implemented the deployment of the central economic work conference, summed up the work in 2018, and deployed the task of 2019 At the meeting, Wang Yong, state councilor, delivered his important instructions on drug supervision Zhang Mao, Secretary of the Party group and director general of the State Administration of market supervision, attended the meeting and put forward requirements for further strengthening drug supervision Liu Shi, member of the Party group of the State Administration of market supervision and leader of the discipline inspection and supervision group of the State Commission for Discipline Inspection and the State Commission for Discipline Inspection stationed in the State Administration of market supervision, attended the meeting Li Li, member of the Party group of the State Administration of market supervision, secretary and deputy director of the Party group of the State Drug Administration, and Jiao Hong, director of the State Drug Administration, attended the meeting and delivered speeches Xu Jinghe, member of the Party group and deputy director general of SDA, Chen Shifei and Yan Jiangying attended the meeting The representatives at the meeting agreed that the important instructions of State Councilor Wang Yong fully affirmed the achievements of drug regulatory work, greatly encouraged the cadres and staff of the national drug regulatory system, and had important guiding significance for drug regulatory work in the new era The whole system should earnestly study and deeply understand, put the instructions of State Councilor Wang Yong in place, practically guarantee the safety and effectiveness of drug use by the people, and strive to create a new situation of drug supervision in the era In his speech, Zhang Mao fully affirmed the achievements of drug regulatory work in 2018 He pointed out that over the past year, the national drug supervision system has thoroughly studied and implemented the spirit of Xi Jinping's new socialist China with Chinese characteristics, the spirit of the nineteen and third Plenary Session of the nineteen and third Plenary Session of the party, conscientiously implemented the decision making and deployment of the Party Central Committee and the State Council, deepened reform and innovation, strengthened daily supervision, and made institutional reform smoothly and orderly We have steadily improved our ability to supervise and improve, and made solid progress in Party building, making remarkable achievements in all aspects of our work He stressed that drug safety is related to the health and well-being of the people, social stability and overall economic development, and the mission of drug supervision system is glorious and arduous Under the firm leadership of the Party Central Committee with Comrade Xi Jinping as the core, we should constantly enhance the political standing, scientifically and accurately judge the requirements of the work situation, take the initiative in putting the work of drug supervision in the overall economic and social situation and put it into the overall supervision of the market, plan and plan, perfect and perfect the supervision system and mechanism, and carry out the local drug regulatory responsibilities of all levels, especially the municipal and county level two market supervision departments We should work hard on the implementation of the four strictest principles, on the prevention of security risks, on the formation of regulatory joint forces, on the acceleration of review and approval, on the construction of system and mechanism, on the strengthening of the party's construction, on the better implementation of the deployment of the Central Committee, to meet the expectations of the masses, to meet the needs of development, to meet the challenges of the situation, and to have stronger responsibilities We will take on responsibilities and work with a more solid work style, make drug supervision more precise, detailed, specialized, superior and stronger, and make every effort to ensure the safety and effectiveness of drug use by the people The meeting pointed out that 2019 is the 70th anniversary of the founding of the people's Republic of China, the key year for building a moderately prosperous society in an all-round way, and the start year for the comprehensive work of the drug regulatory system after the institutional reform The general work guideline for China's drug supervision system should be guided by Xi Jinping's new socialist ideology with Chinese characteristics, thoroughly implement the spirit of the nineteen and third Plenary Session of the party's nineteen and second plenary sessions, and conscientiously implement the "four most stringent" requirements according to the central economic work conference, adhere to the general keynote of the work of "keeping the peace ahead", adhere to the new development concept, and focus on strengthening the management of the life cycle of the drugs Promote the scientific development of supervision as the starting point, focus on reform, safety, quality and foundation, constantly improve the supervision system and mechanism, innovate supervision methods, strengthen risk management, deepen the implementation of responsibilities, improve the scientific, legal, international and modern level of drug supervision, effectively ensure the safety and effectiveness of people's drug use, and strive to write a new era of drug supervision Chapter Li Li pointed out that to profoundly understand the protection of drug safety is a serious political issue, a major economic issue, a basic livelihood issue and a rigorous technical problem We should understand the issue of drug safety from the height of maintaining the party central authority with Comrade Xi Jinping as the core and consolidating the ruling foundation of the party At present, China's drug regulatory work is in the construction period of new drug regulatory system and mechanism, the resolution period of historical problems, the promotion period of high-quality development of drugs, and the reconstruction period of drug regulatory system morale and image The cadres and staff of the drug regulatory system should further strengthen their confidence and work together to push forward the drug regulatory cause Li Li stressed that in order to do a good job in drug supervision this year, we must adhere to one direction and run the "rigorous standards, the most stringent supervision, the most severe punishment and the most serious accountability" put forward by general secretary Xi Jinping, throughout the whole process of drug supervision We should strengthen the investigation and treatment of potential risks, strengthen the supervision of high-risk products such as vaccines, implement the drug safety responsibilities of all parties, and firmly hold the bottom line of drug safety; deepen the reform of review and approval system, optimize government services, support research and development innovation, and pursue high-quality development of drugs We should consolidate the three supports, improve the laws and regulations, establish and improve the drug supervision system, and strengthen the construction of supervision and guarantee capacity We should adhere to and comprehensively strengthen the party's leadership over all aspects of drug supervision and promote the development from strict party governance to in-depth development Jiao Hong has deployed six key tasks in 2019: first, improve the system of laws and standards, and implement the "four strictest" requirements Actively promote the revision and implementation of laws and regulations, and speed up the construction of standard system Second, we will deepen the reform of the review and approval system and promote the high-quality development of the pharmaceutical industry We will accelerate the listing of new drugs, make every effort to promote the evaluation of the quality and efficacy of generic drugs, deepen the reform of the medical device review and approval system, and improve the registration and filing management of cosmetics Third, we will promote the improvement of the vaccine regulatory system and resolutely uphold the bottom line of safety We will strictly implement the power of vaccine supervision, strengthen supervision and inspection, intensify the inspection of the issuance of vaccine batches, and implement the supervision of listing cases Fourth, adhere to the concept of risk management and strictly prevent and control risks We will strengthen supervision over key high-risk products and random inspection and monitoring, and crack down on violations of laws and regulations Fifth, we will promote scientific research in supervision and improve the level of modernization of supervision Sixthly, we should vigorously promote intelligent supervision and continuously innovate supervision methods Jiao Hong put forward three requirements: first, enrich the supervision force, implement the supervision responsibility, compact the main responsibility of the enterprise, and strengthen the responsibility of territorial management Second, strengthen capacity-building, consolidate the regulatory foundation, improve the quality management system of regulatory authorities, establish and improve the drug emergency management mechanism, and promote the improvement of regulatory business capacity Third, enhance the service awareness, enhance the supervision efficiency, practice the service awareness with actions, and establish a new image of drug supervision with honest supervision Representatives of the pharmaceutical supervision departments of all provinces (districts, cities) and Xinjiang production and Construction Corps, departments and bureaus of the State Administration of pharmaceutical supervision and directly affiliated units attended the meeting Representatives of relevant ministries and commissions were invited to attend the meeting.